NasdaqGS - Delayed Quote USD

Pacira BioSciences, Inc. (PCRX)

30.82 -0.69 (-2.19%)
At close: May 17 at 4:00 PM EDT
30.82 0.00 (0.00%)
After hours: May 17 at 4:02 PM EDT
Loading Chart for PCRX
DELL
  • Previous Close 31.51
  • Open 31.56
  • Bid 30.77 x 300
  • Ask 30.89 x 100
  • Day's Range 30.70 - 31.57
  • 52 Week Range 25.33 - 42.63
  • Volume 469,245
  • Avg. Volume 636,600
  • Market Cap (intraday) 1.435B
  • Beta (5Y Monthly) 0.77
  • PE Ratio (TTM) 20.41
  • EPS (TTM) 1.51
  • Earnings Date Jul 31, 2024 - Aug 5, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 46.00

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

www.pacira.com

711

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PCRX

Performance Overview: PCRX

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PCRX
8.65%
S&P 500
11.18%

1-Year Return

PCRX
25.32%
S&P 500
29.04%

3-Year Return

PCRX
50.46%
S&P 500
27.06%

5-Year Return

PCRX
30.63%
S&P 500
84.38%

Compare To: PCRX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PCRX

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    1.43B

  • Enterprise Value

    1.69B

  • Trailing P/E

    20.41

  • Forward P/E

    11.52

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.42

  • Price/Book (mrq)

    1.61

  • Enterprise Value/Revenue

    2.48

  • Enterprise Value/EBITDA

    9.02

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.34%

  • Return on Assets (ttm)

    3.76%

  • Return on Equity (ttm)

    8.49%

  • Revenue (ttm)

    681.75M

  • Net Income Avi to Common (ttm)

    70.47M

  • Diluted EPS (ttm)

    1.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    325.89M

  • Total Debt/Equity (mrq)

    65.21%

  • Levered Free Cash Flow (ttm)

    146.28M

Research Analysis: PCRX

Company Insights: PCRX

Research Reports: PCRX

People Also Watch